CRBU
Caribou Biosciences, Inc.NASDAQHealthcare$1.94-2.51%ClosedMarket Cap: $187.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.51
P/S
16.89
EV/EBITDA
-1.56
DCF Value
$-2.62
FCF Yield
-59.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
88.2%
Operating Margin
-1329.4%
Net Margin
-1327.4%
ROE
-91.5%
ROA
-82.5%
ROIC
-95.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $3.9M | 82.7% | $-28.5M | $-26.5M | $-0.28 | — |
| FY 2025 | $11.2M | 67.3% | $-136.2M | $-148.1M | $-1.59 | — |
| Q3 2025 | $2.2M | 71.3% | $-29.4M | $-27.5M | $-0.30 | — |
| Q2 2025 | $2.7M | 100.0% | $-47.6M | $-54.1M | $-0.58 | — |
| Q1 2025 | $2.4M | 100.0% | $-42.9M | $-40.0M | $-0.43 | — |
| Q4 2024 | $2.1M | -1337.8% | $-38.9M | $-35.5M | $-0.39 | — |
| FY 2024 | $10.0M | 60.7% | $-166.6M | $-149.1M | $-1.65 | — |
| Q3 2024 | $2.0M | 100.0% | $-38.2M | $-34.7M | $-0.38 | — |
| Q2 2024 | $3.5M | 75.3% | $-43.5M | $-37.7M | $-0.42 | — |
| Q1 2024 | $2.4M | 70.8% | $-46.0M | $-41.2M | $-0.46 | — |
| Q4 2023 | $3.6M | 44.5% | $-37.4M | $-34.5M | $-0.39 | — |
| FY 2023 | $34.5M | 89.8% | $-116.1M | $-102.1M | $-1.38 | — |